FDA Panel Backs Approval of a New Drug for Alzheimer’s
source: pixabay.com

FDA Panel Backs Approval of a New Drug for Alzheimer’s

  The FDA advisory panel which is composed of specialists who advise the FDA on brain medications, recently voted 6-0 in agreement on that the new drug, Leqembi, was effective…

Continue Reading FDA Panel Backs Approval of a New Drug for Alzheimer’s
Alzheimer’s Disease: An Influential 2006 Study Containing False Images Leads Scientists To Reverse Previous Theories
source: pixabay.com

Alzheimer’s Disease: An Influential 2006 Study Containing False Images Leads Scientists To Reverse Previous Theories

  The failure rate of drug development for Alzheimer’s is 99 percent according to a recent study. Since 1984 scientists have concentrated on developing treatments to prevent the formation of…

Continue Reading Alzheimer’s Disease: An Influential 2006 Study Containing False Images Leads Scientists To Reverse Previous Theories
AI Can Predict Dementia Fifteen Years Prior to Symptoms Occurring
source: pixabay.com

AI Can Predict Dementia Fifteen Years Prior to Symptoms Occurring

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading AI Can Predict Dementia Fifteen Years Prior to Symptoms Occurring
Study of the Week: A Device That Can Detect Alzheimer’s 17 Years Before Symptoms Start
source: pixabay.com

Study of the Week: A Device That Can Detect Alzheimer’s 17 Years Before Symptoms Start

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: A Device That Can Detect Alzheimer’s 17 Years Before Symptoms Start

Editor’s Choice: A Biomarker for Early Alzheimer’s Detection, A Teen Living with Usher Syndrome, and A Possible Chagas Disease Treatment

Happy Monday! This week, we have details on a method for detecting Alzheimer's 17 years in advance, the story of a teen living with Usher syndrome, and a possible breakthrough…

Continue Reading Editor’s Choice: A Biomarker for Early Alzheimer’s Detection, A Teen Living with Usher Syndrome, and A Possible Chagas Disease Treatment
Alzheimer’s Disease: Study Suggests a Connection Between Digestive Disorders and AD
source: pixabay.com

Alzheimer’s Disease: Study Suggests a Connection Between Digestive Disorders and AD

  The gut-brain axis has recently been mentioned in connection with various disorders. According to an article in SciTechDaily, a study at ECU’s Centre for Precision Health confirms a genetic…

Continue Reading Alzheimer’s Disease: Study Suggests a Connection Between Digestive Disorders and AD

Alzheimer’s: German and UK Scientists Successfully Reduced Alzheimer’s Symptoms in Laboratory Animals

  Eureka Alert recently published a statement by a team of researchers that early results of a new method of treating Alzheimer’s have been “absolutely spectacular.” The new antibody-based therapy…

Continue Reading Alzheimer’s: German and UK Scientists Successfully Reduced Alzheimer’s Symptoms in Laboratory Animals
Alzheimer’s: A 50-year-old FDA Approved Diuretic Restored Normal Brain Activity in Mice; Will It Work On Humans?
source: pixabay.com

Alzheimer’s: A 50-year-old FDA Approved Diuretic Restored Normal Brain Activity in Mice; Will It Work On Humans?

  When you are looking for new treatments that will either stop or slow the development of Alzheimer’s disease, where would you look? According to a recent article in Gladstone…

Continue Reading Alzheimer’s: A 50-year-old FDA Approved Diuretic Restored Normal Brain Activity in Mice; Will It Work On Humans?
 Scientists Announce Breakthrough Discovery for Alzheimer’s and Other Neurological Diseases
source: pixabay.com

 Scientists Announce Breakthrough Discovery for Alzheimer’s and Other Neurological Diseases

   The Times Now News recently featured an article that highlighted a study by a group of NYU Langone scientists. The study paper was published October 6th, 2021 in the…

Continue Reading  Scientists Announce Breakthrough Discovery for Alzheimer’s and Other Neurological Diseases
Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.
source: pixabay.com

Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.

  The pressure was on. Researchers had been studying Alzheimer’s for decades. Every morsel of discovery was hailed as moving closer to a cure and results were always expected soon…

Continue Reading Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.
FDA Approves New Alzheimer’s Drug, But Not Without Controversy
source: pixabay.com

FDA Approves New Alzheimer’s Drug, But Not Without Controversy

According to an announcement from the US Food and Drug Administration (FDA), the agency has recently approved a new therapy for Alzheimer's disease. While this is a significant moment for…

Continue Reading FDA Approves New Alzheimer’s Drug, But Not Without Controversy
Study of the Week: Primary Progressive Aphasia Patients with Alzheimer’s Keep Their Memory
source: pixabay.com

Study of the Week: Primary Progressive Aphasia Patients with Alzheimer’s Keep Their Memory

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Primary Progressive Aphasia Patients with Alzheimer’s Keep Their Memory
Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease
source: pixabay.com

Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease

  There are many common elements in Alzheimer’s disease (AD), which is the most common type of dementia. It is now evident that there are varied spans of disease progression…

Continue Reading Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease
Baylor College Team Discovers the Origin of Alpha-1 Antitrypsin Deficiency in Infants
source: pixabay.com

Baylor College Team Discovers the Origin of Alpha-1 Antitrypsin Deficiency in Infants

  A recent article in Science News highlighted a discovery by Richard Seifes, M.D. of Baylor College of Medicine.  Dr. Seifes has discovered the origin of a liver disease that…

Continue Reading Baylor College Team Discovers the Origin of Alpha-1 Antitrypsin Deficiency in Infants
Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
New Blood Test Improves Alzheimer’s Disease Diagnosis
source: pixabay.com

New Blood Test Improves Alzheimer’s Disease Diagnosis

  A blood test that gives a more accurate diagnosis of Alzheimer’s disease was announced at the July 2020 International Conference of the Alzheimer’s Association. The Association estimates that approximately…

Continue Reading New Blood Test Improves Alzheimer’s Disease Diagnosis
Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
source: pixabay.com

Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets

  As of right now, there are no treatments for Alzheimer's disease, a progressive neurodegenerative disorder. However, that may soon change. A study led by UCLA researchers identified potential drug…

Continue Reading Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
source: pixabay.com

Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease

  According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…

Continue Reading Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
source: pixabay.com

Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward

As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…

Continue Reading Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
source: pixabay.com

Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease

  Parkinson’s News Today recently published an article containing new information about biomarkers in Alzheimer’s disease that can be linked to the early stages of Parkinson’s disease. Many people with…

Continue Reading Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease
Free-Photos / Pixabay

Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease

According to an article in The Asahi Shimbun, Japanese scientists have developed a new vaccine to mitigate neuronal degeneration caused by Alzheimer's disease. The vaccine, delivered nasally, had promising results…

Continue Reading Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease